Furthermore, clinically, we found that downregulation of LZTFL1 in ccRCC may correlate with worse outcome and may be used as a prognostic maker; and overexpression of LZTFL1 in kidney tumors may be a therapeutic strategy against ccRCC. Here, LZTFL1 is linked to kidney neoplasm.